Pfizer to start study evaluating omicron-based COVID vaccine

On Tuesday, Pfizer announced it is starting a clinical study to evaluate the safety, tolerability, and immunogenicity of an omicron-based vaccine in healthy adults who are 18 through 55. Local health experts are weighing in on what’s behind the study and what it means for you.